Advertisement
Julie Zhang
Reporter, Business
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Areas of Expertise:
Corporate finance, IPOSLanguages Spoken:
Cantonese, English, Mandarin
‘Moderate’ upside is possible as investors ‘direct attention back to China somewhat’, assuming trade truce is extended, bank says.
METiS TechBio debuts on Hong Kong stock market as its CEO compares the drug design start-up to SpaceX for the pharmaceutical industry.
Company’s shares jump in Hong Kong and Shenzhen after tie-up that bolsters China’s growing drug innovation profile.
Tech-heavy index breaches the 3,900-point mark amid strong signals from Beijing that it is committed to chip self-sufficiency.
Advertisement
Global investors pile into city’s latest bond sale, with orders 7.6 times oversubscribed, backing its green finance ambitions.
City aims to broaden gold offerings and expand clearing and storage facilities to seize opportunities in the surging market.
AI-powered drug developer Metis TechBio leads group that includes developers of autonomous driving technology and industrial robots.
State Council calls for ‘value-based pricing’ for innovative drugs, a move researchers said would benefit private healthcare players.
The future of treating brain diseases could lie in non-invasive technologies, according to Chongqing Haifu Medical Technology.
About 70 per cent of buyers were end users and 30 per cent investors, with mainland buyers accounting for about 20 per cent of the total.
Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?
The non-invasive BCI technology offers a safer alternative to surgery for some conditions, BrainCo partner Nyx He says.
AI, robotics and energy storage firms make up most of the record-high IPO pipeline in Hong Kong, says Chan.
Hang Seng Healthcare Index outpaces broader market as Akeso, Innovent, Hansoh provide refuge for global investors.
Under pilot rules, at least 65 per cent of capital must come from institutional investors and foreign ownership is capped at 49 per cent.
Citic leads Asia-Pacific in fees in the first quarter as IPOs in Hong Kong and mainland China offset weaker debt and M&A activity.
Sovereign wealth funds from Singapore and Abu Dhabi join Chinese state capital as cross-border biotech licensing reaches record highs.
As pharmaceutical firms navigate China’s aggressive pricing reforms, their profits could be squeezed further this year.
Mainland’s stock market watchdog is discouraging establishment of ‘red-chip-structured’ companies in sensitive industries.
Analysts say the delay is most likely administrative and that the overall plan is still on track.
China’s falling fertility rate sees spike in demand for assisted reproduction as biotech firm raises US$101 million from Hong Kong listing.
Reaching development, regulatory and commercial milestones could see value of deal hit around US$2.75 billion.
Sequencio, CK Life’s new Hong Kong unit, is advancing about 20 cancer vaccine projects as China pathway offers faster route to human trials.
All 123 units at Chester were sold, with strong demand pointing to a steady recovery in Hong Kong’s residential sector.
Hong Kong government-backed investor says strong returns and co-investment flows are reinforcing the region’s appeal to global capital.
Hospital-network operator delays plan to raise up to US$115 million amid tepid demand.
Patent expiry of blockbuster drug opens door for Chinese drug makers to challenge multinationals in booming weight-loss market.
Sichuan-based Keymed expects to receive up to US$320 million as a result of deal involving its autoimmune disease treatment licensed in 2024.
Advanced manufacturing and healthcare attract more attention at the expense of technology, media and telecommunications, Bain & Co says.
